Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22728644 | 0.90 | GAA (0.38) | GAAL3MBTL1 | |
| SCHEMBL11696413 | 0.82 | CNR2 (0.43) | GAAL3MBTL1BACE1LMNA | |
| SCHEMBL576153 | 0.79 | GAA (0.39) | GAAL3MBTL1BACE1HPGDALOX12 | |
| SCHEMBL22728705 | 0.74 | NAAA (0.39) | TAAR1 | |
| SCHEMBL22013858 | 0.72 | GAA (0.41) | GAAL3MBTL1ATMHPGDALOX12 | |
| SCHEMBL7997821 | 0.72 | GAA (0.41) | GAAL3MBTL1ATMHPGDALOX12 | |
| SCHEMBL9139804 | 0.71 | — | — | |
| SCHEMBL9251968 | 0.71 | TSHR (0.50) | GAAL3MBTL1BACE1ATMLMNA | |
| SCHEMBL22728634 | 0.71 | HTR7 (0.41) | — | |
| SCHEMBL22015030 | 0.70 | GAA (0.48) | GAAL3MBTL1BACE1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024479-A1 | SYSTEMS AND METHODS FOR REGIOSELECTIVE CARBONYLATION OF 2,2-DISUBSTITUTED EPOXIDES FOR THE PRODUCTION OF ALPHA,ALPHA-DISUBSTITUTED BETA-LACTONES | CORNELL UNIVERSITY | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024479-A1 | SYSTEMS AND METHODS FOR REGIOSELECTIVE CARBONYLATION OF 2,2-DISUBSTITUTED EPOXIDES FOR THE PRODUCTION OF ALPHA,ALPHA-DISUBSTITUTED BETA-LACTONES | DCXR, CBR3, CBR1 | GAA 522/4885L3MBTL1 3495/4885BACE1 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.